Is EYLEA up or down today?
EYLEA is up 0.98% today, last at 404.33. This stock moved +0.98% versus the prior close.
EYLEA · EYLEA
EYLEA (EYLEA) is trading at 404.33, up 0.98% on the session. EYLEA sits at the 50% mark of its 52-week range, carries a 14-day RSI of 49, and trades above its 50-day average. Over the past month it is up 1.32%.
Leading the coverage: “EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs. Eylea May Be Overblown (EYPT) - Seeking Alpha” (Google News Company, 24d ago). EYLEA is +0.85% since story.
EYLEA trades on a trailing P/E of 17.7 and is running 2.38% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
EYLEA is up 0.98% today, last at 404.33. This stock moved +0.98% versus the prior close.
Leading the coverage: “EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs. Eylea May Be Overblown (EYPT) - Seeking Alpha” (Google News Company, 24d ago). EYLEA is +0.85% since story. Dominant story: EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs. Eylea May Be Overblown (EYPT) - Seeking Alpha (1 source, bearish) RSI is 49 — neutral Price below 50-day average — short-term weakness Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (181 days) · Drag or scroll left for earlier dates
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs. Eylea May Be Overblown (EYPT) - Seeking Alpha
EyePoint’s Duravyu falls short to Eylea in Phase III trial - Yahoo Finance
Regeneron Pharma Q2 Earnings: EYLEA HD Outsold EYLEA for the First Time - TIKR.com
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength - Yahoo Finance
[Regeneron Pharmaceuticals Q2 2026 Earnings Call] Dupixent Tops $6 Billion, EYLEA HD Overtakes Legacy Drug for First Time as Regeneron Revenue Surges 17% - finance.biggo.com